Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Karin Holmskov, Hansen"'
Autor:
Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Harsløf, Laila Belcaid, Julie Gehl, Lise Søndergaard, Rikke Løvendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, Trine Heide Oellegaard, Christina Westmose Yde, Lise Barlebo Ahlborn, Ulrik Lassen
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estim
Externí odkaz:
https://doaj.org/article/904750a8228c462b9f8145bcff4832b1
Autor:
Scott N. Gettinger, MD, Rudolf M. Huber, MD, PhD, Dong-Wan Kim, MD, PhD, Lyudmila Bazhenova, MD, Karin Holmskov Hansen, MD, Marcello Tiseo, MD, Corey J. Langer, MD, FACP, Luis G. Paz-Ares Rodríguez, MD, PhD, Howard L. West, MD, Karen L. Reckamp, MD, MS, Glen J. Weiss, MD, Egbert F. Smit, MD, PhD, Maximilian J. Hochmair, MD, Sang-We Kim, MD, PhD, Myung-Ju Ahn, MD, PhD, Edward S. Kim, MD, FACP, Harry J.M. Groen, MD, PhD, Joanna Pye, MS, Yuyin Liu, PhD, Pingkuan Zhang, MD, Florin Vranceanu, MD, PhD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100385- (2022)
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced maligna
Externí odkaz:
https://doaj.org/article/78d40f5a880944a8b24323de142222e5
Autor:
Birgitte Bjørnhart, Karin Holmskov Hansen, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte
Publikováno v:
Thrombosis Update, Vol 4, Iss , Pp 100056- (2021)
Background: Besides the cancer itself, venous thromboembolism (VTE) is the leading cause of death in cancer patients receiving outpatient chemotherapy (CT). Data on VTE development and impact on treatment course and outcome in real-life NSCLC patient
Externí odkaz:
https://doaj.org/article/dc14b99456fa443a8f009f5dea9da707
Publikováno v:
EBioMedicine, Vol 63, Iss , Pp 103184- (2021)
Externí odkaz:
https://doaj.org/article/6a69767dae5647cc860caf42f8345bb9
Autor:
Birgitte Bjørnhart, Charlotte Kristiansen, Jon Asmussen, Karin Holmskov Hansen, Kim Wedervang, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte
Publikováno v:
Thrombosis research. 221
Prospective investigation on cancer-associated venous thromboembolism (VTE) in non-small cell lung cancer (NSCLC) during treatment with immune checkpoint inhibitors (ICIs) is lacking.A prospective real-world study using combined computed tomography v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c63ed0d996875cbb1b540463039d6278
https://pubmed.ncbi.nlm.nih.gov/36396518
https://pubmed.ncbi.nlm.nih.gov/36396518
Autor:
Inger Johanne Zwicky Eide, Simone Stensgaard, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicenas, Jussi Koivunen, Bjørn Henning Grønberg, Boe Sandahl Sørensen, Odd Terje Brustugun
Publikováno v:
Eide, I J Z, Stensgaard, S, Helland, Å, Ekman, S, Mellemgaard, A, Hansen, K H, Cicenas, S, Koivunen, J, Grønberg, B H, Sørensen, B S & Brustugun, O T 2022, ' Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations : a post-hoc subgroup analysis with pooled data from two phase II clinical trials ', Translational Lung Cancer Research, vol. 11, no. 6, pp. 953-963 . https://doi.org/10.21037/tlcr-21-995
Translational Lung Cancer Research (TLCR)
Translational Lung Cancer Research (TLCR)
Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 is largely unknown. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf92d28602e537f5a1f22275cc40a2cd
https://pure.au.dk/portal/da/publications/osimertinib-in-nonsmall-cell-lung-cancer-with-uncommon-egfrmutations(f24c391e-f99d-4b57-abe6-9af9f1018ea3).html
https://pure.au.dk/portal/da/publications/osimertinib-in-nonsmall-cell-lung-cancer-with-uncommon-egfrmutations(f24c391e-f99d-4b57-abe6-9af9f1018ea3).html
Autor:
Birgitte Bjørnhart, Karin Holmskov Hansen, Jon Thor Asmussen, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte
Publikováno v:
Bjørnhart, B, Hansen, K H, Asmussen, J T, Jørgensen, T L, Herrstedt, J & Schytte, T 2022, ' Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis ', Cancers, vol. 14, no. 7, 1682 . https://doi.org/10.3390/cancers14071682
Cancers; Volume 14; Issue 7; Pages: 1682
Cancers; Volume 14; Issue 7; Pages: 1682
Sparse data exist on immune checkpoint inhibition (ICI) in NSCLC patients with brain metastasis (BM), especially for those with no local therapy (LT) (whole brain radiation therapy (WBRT), stereotactic RT (SRT) or neurosurgery) preceding ICI. Our aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d25c924d724c8304d4feb76af7234cd
https://findresearcher.sdu.dk:8443/ws/files/201698074/cancers_14_01682.pdf
https://findresearcher.sdu.dk:8443/ws/files/201698074/cancers_14_01682.pdf
Autor:
Susanne Oksbjerg Dalton, Karin Holmskov Hansen, Niels Lyhne Christensen, Torben Riis Rasmussen, Jane Christensen
Publikováno v:
Christensen, N L, Rasmussen, T R, Hansen, K H, Christensen, J & Dalton, S O 2020, ' Comorbidity and early death in Danish stage I lung cancer patients–an individualised approach ', Acta Oncologica, vol. 59, no. 8, pp. 994-1001 . https://doi.org/10.1080/0284186X.2020.1764096
Christensen, N L, Rasmussen, T R, Hansen, K H, Christensen, J & Dalton, S O 2020, ' Comorbidity and early death in Danish stage I lung cancer patients-an individualised approach ', Acta Oncologica, vol. 59, no. 8, pp. 994-1001 . https://doi.org/10.1080/0284186X.2020.1764096
Christensen, N L, Rasmussen, T R, Hansen, K H, Christensen, J & Dalton, S O 2020, ' Comorbidity and early death in Danish stage I lung cancer patients-an individualised approach ', Acta Oncologica, vol. 59, no. 8, pp. 994-1001 . https://doi.org/10.1080/0284186X.2020.1764096
Background: Comorbidity is an important prognostic marker and a treatment indicator for lung cancer patients. Register-based studies often describe the burden of comorbidity by the Charlson comorbidity index (CCI) based on hospital discharge data. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d71ef4eb2bf9bb3e40d117cc0af233c
https://doi.org/10.1080/0284186x.2020.1764096
https://doi.org/10.1080/0284186x.2020.1764096
Autor:
Dong Wan Kim, Edward S. Kim, Egbert F. Smit, Maximilian Hochmair, Sang We Kim, Howard West, Marcello Tiseo, Rudolf M. Huber, Karin Holmskov Hansen, Harry J.M. Groen, Karen L. Reckamp, Myung-Ju Ahn, Luis Paz-Ares Rodríguez, Scott N. Gettinger, David Kerstein, Natasha B. Leighl, D. Ross Camidge, Corey J. Langer
Publikováno v:
Journal of Thoracic Oncology, 15(3), 404-415. ELSEVIER SCIENCE INC
Journal of Thoracic Oncology, 15(3), 404-415. International Association for the Study of Lung Cancer
Huber, R M, Hansen, K H, Paz-Ares Rodríguez, L, West, H L, Reckamp, K L, Leighl, N B, Tiseo, M, Smit, E F, Kim, D-W, Gettinger, S N, Hochmair, M J, Kim, S-W, Langer, C J, Ahn, M-J, Kim, E S, Kerstein, D, Groen, H J M & Camidge, D R 2020, ' Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial ', Journal of Thoracic Oncology, vol. 15, no. 3, pp. 404-415 . https://doi.org/10.1016/j.jtho.2019.11.004
Huber, R M, Hansen, K H, Paz-Ares Rodríguez, L, West, H L, Reckamp, K L, Leighl, N B, Tiseo, M, Smit, E F, Kim, D W, Gettinger, S N, Hochmair, M J, Kim, S W, Langer, C J, Ahn, M J, Kim, E S, Kerstein, D, Groen, H J M & Camidge, D R 2020, ' Brigatinib in Crizotinib-Refractory ALK+ NSCLC : 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial ', Journal of Thoracic Oncology, vol. 15, no. 3, pp. 404-415 . https://doi.org/10.1016/j.jtho.2019.11.004
Journal of Thoracic Oncology, 15(3), 404-415. International Association for the Study of Lung Cancer
Huber, R M, Hansen, K H, Paz-Ares Rodríguez, L, West, H L, Reckamp, K L, Leighl, N B, Tiseo, M, Smit, E F, Kim, D-W, Gettinger, S N, Hochmair, M J, Kim, S-W, Langer, C J, Ahn, M-J, Kim, E S, Kerstein, D, Groen, H J M & Camidge, D R 2020, ' Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial ', Journal of Thoracic Oncology, vol. 15, no. 3, pp. 404-415 . https://doi.org/10.1016/j.jtho.2019.11.004
Huber, R M, Hansen, K H, Paz-Ares Rodríguez, L, West, H L, Reckamp, K L, Leighl, N B, Tiseo, M, Smit, E F, Kim, D W, Gettinger, S N, Hochmair, M J, Kim, S W, Langer, C J, Ahn, M J, Kim, E S, Kerstein, D, Groen, H J M & Camidge, D R 2020, ' Brigatinib in Crizotinib-Refractory ALK+ NSCLC : 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial ', Journal of Thoracic Oncology, vol. 15, no. 3, pp. 404-415 . https://doi.org/10.1016/j.jtho.2019.11.004
Introduction: We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase-positive NSCLC.Methods: Patients were randomized 1:1 to take either oral brigatinib 90 mg once daily (arm A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc1538877c3ac1cc145cc653dfa977fc
https://doi.org/10.1016/j.jtho.2019.11.004
https://doi.org/10.1016/j.jtho.2019.11.004
Autor:
Inger Johanne Zwicky, Eide, Simone, Stensgaard, Åslaug, Helland, Simon, Ekman, Anders, Mellemgaard, Karin Holmskov, Hansen, Saulius, Cicenas, Jussi, Koivunen, Bjørn Henning, Grønberg, Boe Sandahl, Sørensen, Odd Terje, Brustugun
Publikováno v:
Translational lung cancer research. 11(6)
Osimertinib is standard of care forWe identified patients with uncommonOf 299 enrolled patients in the two trials, 21 patients with uncommon mutations were identified; 12 patients had a single mutation (G719X or L861Q), one patient had L861Q and an e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bbd0f24101628cf538fd982611fac652
https://pubmed.ncbi.nlm.nih.gov/35958324
https://pubmed.ncbi.nlm.nih.gov/35958324